Viewing nowPregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Medika Korea Co., Ltd.

MFDS item code 201109309 · Approved 2011.10.31 · Insurance code 646003640
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medication helps relieve peripheral and central neuropathic pain in adults and assists in managing symptoms of partial seizures in epilepsy patients. It is also used for the treatment of pain associated with fibromyalgia. Therefore, this medication improves various neuropathic pains and seizure symptoms.
Administer the total daily dose of this medicine, which contains pregabalin, orally in 2 divided doses, with or without food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See '5. Patients with renal impairment') 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See '4. Discontinuation of treatment') 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be stopped gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys in unchanged form. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: The supplemental dose is a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so any mood changes or unusual behaviors during use should be reported to a healthcare professional immediately. The use of this medication is not recommended in individuals with allergies to any ingredient in this medication or genetic issues such as lactose intolerance. Diabetes patients should be cautious as weight gain may require adjustments to blood sugar control medications. If severe allergic reactions like angioedema occur, administration should be immediately stopped and medical advice should be sought. Elderly patients should be particularly cautious during initial use as they may be at risk for falls or injuries due to dizziness or drowsiness. Blurred vision or other eye symptoms may occur, and if these symptoms develop, the medication should be stopped, or healthcare professional should be consulted. Discontinuing this medication suddenly can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be gradually reduced as per healthcare provider's instructions. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should be monitored closely. Patients with decreased kidney function may require dosage adjustments. Patients with heart disease should use this medication with caution, particularly those with congestive heart failure. Caution should be taken when using this medication in combination with opioid analgesics as it may increase the risk of central nervous system depression. Patients with respiratory or neurological diseases, kidney disorders, or elderly patients have a higher risk of severe respiratory suppression, so consultation with a healthcare professional is recommended when taking this medication. Pregnant women should avoid this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding mothers should consider stopping breastfeeding or discontinuing the medication as it may affect infants through breast milk. Patients should be cautious when engaging in hazardous activities such as driving or operating machinery, as dizziness or drowsiness may occur due to this medication. In case of overdose, symptoms may include confusion, drowsiness, depression, and seizures, and immediate medical attention should be sought. This medication should be kept out of the reach of children, and transferring it to another container may cause accidents, so care should be taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, at room temperature between 15°C and 30°C. Storing it this way will help maintain the medication's effectiveness for a long time.
Hard capsule with a reddish-brown upper part and a white lower part containing a white or pale yellow powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Medika Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.